ZJK Industrial Co., Ltd financials

ZJK CIK 0001941506

Source: EDGAR filings · Built 2026-06-19T03:25:50Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2024FY 2024
EBITDA 10.25M 2.21M 6.79M 6.66M
Working Capital 27.43M 19.52M 13.35M
Net Debt -6.94M -7.95M -1.63M
Gross Margin 43.67% 35.88% 37.93% 36.36%
Operating Margin 16.87% 4.32% 21.62% 25.32%
Net Margin 18.10% 9.69% 26.47% 29.36%
Return on Equity (ROE) 23.36% 12.19% 35.43% 50.29%
Return on Assets (ROA) 12.77% 6.61% 20.09%
Current Ratio 1.85× 1.81× 1.85×
Debt-to-Equity 0.17× 0.14× 0.05×
Effective Tax Rate 26.54% 25.67% 14.31% 13.26%
Cash Conversion Ratio 0.65× 1.46× 0.54× 0.11×
Accruals Ratio 0.05× -0.03× 0.09×
SBC % of Revenue 3.42%

Income Statement

Concept FY 2025FY 2024FY 2024FY 2024
Revenues 56.10M 37.81M 29.06M 24.79M
Cost of Revenue 31.60M 24.24M 18.03M 15.78M
Gross Profit 24.50M 13.57M 11.02M 9.01M
Research and Development Expense 1.11M 548.12K 455.40K 487.54K
Operating Expenses 15.04M 11.93M 4.74M 2.74M
Operating Income (Loss) 9.46M 1.63M 6.28M 6.28M
Income Tax Expense (Benefit) 3.67M 1.26M 1.28M 1.11M
Earnings Per Share, Basic $0.16 $0.06 $0.13 $0.12
Weighted Average Number of Shares Outstanding, Basic 62.50M 60.34M 60.00M 60.00M
Earnings Per Share, Diluted $0.16 $0.06 $0.13 $0.12
Weighted Average Number of Shares Outstanding, Diluted 62.62M 60.34M 60.00M 60.00M

Balance Sheet

Concept FY 2025FY 2024FY 2024FY 2024
Cash and Cash Equivalents, at Carrying Value 14.35M 12.26M 2.83M
Assets, Current 59.53M 43.50M 29.10M
Assets 79.53M 55.37M 38.28M
Liabilities, Current 32.10M 23.98M 15.75M
Liabilities 35.93M 25.31M 16.58M
Stockholders' Equity Attributable to Parent 43.47M 30.04M 21.70M
Common Stock, Shares, Outstanding 61.38M 63.82M 61.38M

Cash Flow Statement

Concept FY 2025FY 2024FY 2024FY 2024
Net Cash Provided by (Used in) Operating Activities 6.56M 5.34M 4.12M 814.63K
Net Cash Provided by (Used in) Investing Activities -2.58M -2.80M 1.29M -289.75K
Net Cash Provided by (Used in) Financing Activities -1.01M 6.75M -2.95M -357.65K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ZJK CIK 0001941506), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BEIGF

BEONE MEDICINES LTD.

IKT

INHIBIKASE THERAPEUTICS, INC.

SAR

SARATOGA INVESTMENT CORP.